Stephanie K. Dougan - Concepedia

Author

Stephanie K. Dougan

Also Known As

Andrew J. Aguirre, S. Dougan, S. K. Dougan, Stephanie Dougan, Stephanie K Dougan, Stephanie K. Dougan, Stephanie K. Dougan

308

Publications

10.4K

Citations

H-Index

Concepts

All Affiliations

Harvard University Dana-Farber Cancer Institute Whitehead Institute for Biomedical Research Massachusetts General Hospital Massachusetts Institute of Technology

About

Stephanie K. Dougan is an author at Harvard University specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	26	4.4K
2	Natural Sciences	4	4	418
3	Allergy	3	3	264
4	Biochemistry	3	3	187
5	Engineering	1	1	33

Stephanie K. Dougan

Publications

7.6K

Citations

H-Index

Page 1

	Year	Citations
Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining Takeshi Maruyama, Stephanie K. Dougan, Matthias C. Truttmann, Nature Biotechnology Nonhomologous End JoiningGeneticsPrecise GenomeMolecular BiologyGenetic Engineering	2015	1.1K
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion Yu‐Hwa Huang, Chen Zhu, Yasuyuki Kondo, Nature Tim-3-mediated ToleranceSignal TransductionPhysiologyCellular Regulatory MechanismSelf-tolerance	2014	703
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy Adrienne Luoma, Shengbao Suo, Hannah L. Williams, Cell InflammationCancer ImmunosurveillanceMucosal ImmunologyColon Inflammation InducedImmunology	2020	446
The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy Jordan A. Krall, Ferenc Reinhardt, Oblaise Mercury, Science Translational Medicine	2018	416
In vivo discovery of immunotherapy targets in the tumour microenvironment Penghui Zhou, Donald R. Shaffer, Diana Alvarez Arias, Nature Tumor BiologyImmune EvasionTumor ImmunologyCancer ImmunosurveillanceImmunology	2014	234
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer Katherine L. Morel, Anjali V. Sheahan, Deborah L. Burkhart, Nature Cancer Ezh2 InhibitionDsrna–sting–interferon StressMedicineCancer Cell BiologyTumor Suppressor	2021	228
Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes Jiahai Shi, Lenka Kundrat, Novalia Pishesha, Proceedings of the National Academy of Sciences	2014	207
Sortase-catalyzed transformations that improve the properties of cytokines Maximilian W. Popp, Stephanie K. Dougan, Tzu-Ying Chuang, Proceedings of the National Academy of Sciences Protein AssemblyPeptide EngineeringGlycobiologyMolecular BiologyRecombinant Protein Therapeutics	2011	184
Profiling lymphocyte interactions at the single-cell level by microfluidic cell pairing Burak Dura, Stephanie K. Dougan, Marta Barisa, Nature Communications	2015	182
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer Julien Dilly, Megan T. Hoffman, Laleh Abbassi, Cancer Discovery Kras InhibitorsPancreatic CancerOncogenic AgentMedicineReceptor Tyrosine Kinase	2024	182

Page 1